Clinical evaluation of omalizumab combined with budesonide and salbutamol in the treatment of severe asthma
Zhai Shina
Xie Qiannan
Yang Tao
Abstract：Objective To investigate the clinical efficacy of omalizumab combined with budesonide and salbutamol in the treatment of severe asthma.Methods A total of 62 patients with severe asthma admitted to Huanghe Sanmenxia Hospital from June 2023 to December 2024 were divided into the experimental group and the control group according to the random number table method,with 31 cases in each group.The control group was treated with budesonide combined with salbutamol sulfate,while the ex-perimental group received additional treatment with omalizumab based on the therapeutic regimen of the control group.All patients received continuous treatment for 4 months.The clinical efficacy,asthma control level,quality of life scores,pulmonary function in-dicators,immune function indicators,inflammatory indicators and the occurrence of adverse reactions between the two groups were compared.Results The total effective rate in the experimental group was 93.55%(29/31),which was higher than that in the control group(74.19%(23/31)),and the difference was statistically significant(χ2=4.292,P=0.038).After treatment,the scores of Asthma Control Test and Asthma Quality of Life Questionnaire in the experimental group((23.38±4.10)points,(28.32±5.10)points,respec-tively)were both higher than those in the control group((20.52±3.41)points,(23.52±5.41)points,respectively),and the differences were statistically significant(t=2.986,3.595,both P<0.05).After treatment,forced vital capacity,forced expiratory volume in the first second,and the forced expiratory volume in the first second percent predicted in the experimental group((2.52±0.26)L,(2.11±0.19)L,and(76.30±13.27)%,respectively)were all higher than those of the control group((2.19±0.22)L,(1.83±0.22)L,and(68.73±13.52)%,respectively),and the differences were statistically significant(t=5.395,5.363,2.225,all P<0.05).After treatment,the levels of immunoglobulin A and immunoglobulin G in the experimental group((3.15±0.38)g·L-1 and(13.73±2.05)g·L-1,respectively)were both higher than those of the control group((2.51±0.25)g·L-1 and(10.32±1.42)g·L-1,respectively),and the differences were statisti-cally significant(t=7.834,7.613,both P<0.05).After treatment,the level of immunoglobulin E in the experimental group((235.70±28.21)IU·mL-1)was lower than that in the control group((268.20±34.28)IU·mL-1),and the difference was statistically significant(t=4.076,P<0.05).After treatment,the number of eosinophils in the peripheral blood,the levels of high-sensitivity C-reactive protein and interleukin-6 in the experimental group((0.34±0.08)×109·L-1,(0.87±0.14)mg·L-1,and(9.43±1.79)ng·L-1,respectively)were low-er than those in the control group((0.41±0.09)×109·L-1,(1.58±0.20)mg·L-1,and(13.01±2.39)ng·L-1,respectively),and the differences were statistically significant(t=3.237,16.193,6.675,all P<0.05).The incidence of adverse reactions in the control group and the ex-perimental group(19.35%(6/31)vs 16.13%(5/31))showed no statistically significant difference(χ2=0.111,P>0.05).Conclusion In the treatment of severe asthma,omalizumab combined with budesonide and salbutamol can effectively control asthma,improve pulmonary function and immune function,suppress inflammatory responses,enhance clinical efficacy and quality of life,and has good safety.
Keywords：OmalizumabBudesonideSalbutamolSevere asthmaClinical efficacy
Publication Date：2025-09-25
Online Publishing Date：2025-10-10(First online date of this platform, not the publication date of the document)
Pages：5( 996-1000 )